Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1966 Target Snapshot

Dihydroorotate dehydrogenase (quinone), mitochondrial · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,908Compounds
293Assays
5Approved Drugs
3,508.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Dihydroorotate dehydrogenase (quinone), mitochondrial shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q02127. Start with multiple sclerosis, then reuse UniProt Q02127 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with multiple sclerosis, then reuse UniProt Q02127 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
multiple sclerosis

Dihydroorotate dehydrogenase (quinone), mitochondrial shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include TERIFLUNOMIDE, VIDOFLUDIMUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dihydroorotate dehydrogenase (quinone), mitochondrial as ChEMBL target CHEMBL1966, mapped to UniProt Q02127. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dihydroorotate dehydrogenase (quinone), mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1966
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q02127
Dihydroorotate dehydrogenase (quinone), mitochondrial
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dihydroorotate dehydrogenase (quinone), mitochondrial is the right protein anchor across sources, using UniProt Q02127 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why multiple sclerosis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameDihydroorotate dehydrogenase (quinone), mitochondrial
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ02127
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDihydroorotate dehydrogenase (quinone), mitochondrial
UniProt AccessionQ02127
Component TypeProtein
Sequence Length395 aa

Dihydroorotate dehydrogenase (quinone), mitochondrial

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Dihydroorotate dehydrogenase (quinone), mitochondrial, mapped to UniProt Q02127. Sequence length is 395 aa.

Mapped IDQ02127
Review nameDihydroorotate dehydrogenase (quinone), mitochondrial
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Dihydroorotate dehydrogenase (quinone), mitochondrial shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
multiple sclerosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugTERIFLUNOMIDE
Linked drugVIDOFLUDIMUS
Approved-linked Approved
relapsing-remitting multiple sclerosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugTERIFLUNOMIDE
Linked drugVIDOFLUDIMUS
Approved-linked Approved
rheumatoid arthritis
2 linked drugs · 2 direct · 2 efficacy
Linked drugLEFLUNOMIDE
Linked drugVIDOFLUDIMUS
Approved-linked Approved
psoriatic arthritis
1 linked drug · 1 direct · 1 efficacy
Linked drugLEFLUNOMIDE
Late clinical Phase III
COVID-19
3 linked drugs · 3 direct · 3 efficacy
Linked drugBREQUINAR
Linked drugLEFLUNOMIDE
Linked drugVIDOFLUDIMUS
Late clinical Phase III
Central Nervous System Neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugLEFLUNOMIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include TERIFLUNOMIDE, VIDOFLUDIMUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemultiple sclerosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
2
Phase III
12
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC503,211.0
KI265.0
EC5026.0
KD6.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4744558 9.92 IC50 0.12 Preclinical
CHEMBL5077700 9.75 IC50 0.179 Preclinical
CHEMBL5405642 9.74 IC50 0.18 Preclinical
CHEMBL5075013 9.72 IC50 0.192 Preclinical
CHEMBL5085549 9.72 IC50 0.19 Preclinical
CHEMBL5083643 9.71 IC50 0.195 Preclinical
CHEMBL4854356 9.7 IC50 0.2 Preclinical
CHEMBL5092899 9.7 IC50 0.202 Preclinical
CHEMBL5180161 9.7 IC50 0.2 Preclinical
CHEMBL5590963 9.7 IC50 0.2 Preclinical
Distribution

pChEMBL Value Distribution

190
5.0
213
5.5
275
6.0
305
6.5
381
7.0
420
7.5
293
8.0
140
8.5
80
9.0
36
9.5
pChEMBL
Approved Drugs

Approved Drugs

TERIFLUNOMIDE
CHEMBL973
Approved 2012
Properties Compare Identifier
LEFLUNOMIDE
CHEMBL960
Approved 1998
Properties Compare Identifier
Assay Landscape

Assay Landscape

293
Total Assays
1,925
Tested Compounds
4
Assay Types
Binding — 282 assays, 1,925 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 125 1,533 7.0
cell-based format 113 41 6.9
assay format 43 351 6.8
subcellular format 1 0 —
ADME — 7 assays, 23 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 1 5.4
cell-based format 2 1 6.5
single protein format 2 21 5.9
Functional — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 1 7.7
Toxicity — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine